» Articles » PMID: 39431151

Survey of Hepatitis B Vaccination Coverage and Surface Antibody-Positive Rates in People Aged 1-59 Years in 2006 and 2024

Overview
Date 2024 Oct 21
PMID 39431151
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Implementing hepatitis B vaccination is an important strategy to reduce hepatitis B virus infection and disease burden. Suboptimal adult hepatitis B vaccination coverage limits the further reduction of hepatitis B virus infection.

Methods: A multistage stratified random sampling method was adopted to survey the permanent population aged 1-59 in 2006 and 2024. We calculated the vaccination coverage rate, hepatitis B surface antibody (HBsAb)-positive rate, rate difference, and their 95% confidence intervals (CIs) of the 2 survey populations, and used the 95% CI and χ test to determine whether the difference in rate was statistically significant.

Results: Six hundred twenty-three people were surveyed in 2006 and 606 people were surveyed in 2024. From 2006 to 2024, the hepatitis B vaccination coverage among people aged 1-59 years increased from 54.1% to 78.9%, and the HBsAb-positive rate increased from 46.2% to 57.6%. There was no significant difference in vaccination coverage in the population <15 years of age, but the antibody-positive rate increased significantly. The vaccination coverage rate of the 15-59 age group increased significantly, but there was no statistical difference in the antibody positivity rate of the 15-49 age group, and the antibody positivity rate of the 50-59 age group increased significantly.

Conclusions: Hepatitis B vaccination coverage among adults was still insufficient. Hepatitis B vaccine-mediated immunity was low in adults aged 30-49 years. It is recommended to update the guidelines for hepatitis B vaccination of adults in China, cancel the assessment of risk factors and prevaccination serological screening, and emphasize universal vaccination of all unvaccinated adults to increase coverage.

References
1.
Cui F, Shen L, Li L, Wang H, Wang F, Bi S . Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China. Emerg Infect Dis. 2017; 23(5):765-772. PMC: 5403029. DOI: 10.3201/eid2305.161477. View

2.
Zhang L, Zhang W, Lyu J, Zhang J, Liu J, Yan B . [Comparison of antibody persistence after primary immunization with 5 μg and 10 μg recombinant hepatitis B vaccine among newborns with normal and high response: a five-year following-up]. Zhonghua Liu Xing Bing Xue Za Zhi. 2017; 38(9):1156-1160. DOI: 10.3760/cma.j.issn.0254-6450.2017.09.002. View

3.
Lu P, Hung M, Srivastav A, Grohskopf L, Kobayashi M, Harris A . Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. MMWR Surveill Summ. 2021; 70(3):1-26. PMC: 8162796. DOI: 10.15585/mmwr.ss7003a1. View

4.
Liu Z, Wang Y, Wang W . [Study on changes in hepatitis B incidence in China, 1990-2017]. Zhonghua Liu Xing Bing Xue Za Zhi. 2021; 42(4):613-619. DOI: 10.3760/cma.j.cn112338-20201026-01281. View

5.
Haile K, Timerga A, Mose A, Mekonnen Z . Hepatitis B vaccination status and associated factors among students of medicine and health sciences in Wolkite University, Southwest Ethiopia: A cross-sectional study. PLoS One. 2021; 16(9):e0257621. PMC: 8454964. DOI: 10.1371/journal.pone.0257621. View